The UK’s leading life science companies have today warned that leaving the EU could add risk to the wealth and health of the nation by bringing uncertainty to the industry, adding barriers to investment in the UK and threatening access to the latest medicines.
In a letter to The Observer, the chief executives of the Association of British Pharmaceutical Industries (ABPI); Glaxo SmithKline; AstraZeneca, and the BioIndustry Association are among more than 90 signatories who claim that the future success of the UK life sciences sector is underpinned by being part of the EU’s single market, and EU regulatory…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
